Holen Sie sich die Stockscreener-App
16.11
1.29%
-0.2307
Schlusskurs vom Vortag:
$16.34
Offen:
$15.94
24-Stunden-Volumen:
145.20K
Relative Volume:
0.16
Marktkapitalisierung:
$1.80B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-7.4927
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
-1.77%
1M Leistung:
-32.43%
6M Leistung:
-15.20%
1J Leistung:
-19.07%
1-Tages-Spanne:
$15.82
$16.70
1-Wochen-Bereich:
$15.70
$17.27
52-Wochen-Spanne:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
16.10 | 1.80B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.93 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.78 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.51 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
229.93 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.81 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Head to Head Survey: NewAmsterdam Pharma (NASDAQ:NAMS) vs. Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Is NewAmsterdam Pharma Company NV (NASDAQ: NAMS) A Good Investment Now? - Stocksregister
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares By Investing.com - Investing.com Canada
NewAmsterdam Pharma adds Adele Gulfo to its Board By Investing.com - Investing.com South Africa
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares - Investing.com Australia
NewAmsterdam Pharma adds Adele Gulfo to its Board - Investing.com
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - GlobeNewswire
Blockbuster Drug Veteran Who Led $12B Pfizer Unit Joins NewAmsterdam Board Before Critical Launch - Stock Titan
Arrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Sei Investments Co. Sells 14,456 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Insider Monkey
KLP Kapitalforvaltning AS Purchases Shares of 6,000 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low – Here’s Why - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Average Price Target from Analysts - Defense World
Where are the Opportunities in (NAMSW) - news.stocktradersdaily.com
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Team: 133,000 Shares Granted to Strategic New Hires - Stock Titan
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - MarketScreener
American Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Teacher Retirement System of Texas Makes New $276,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
When (NAMS) Moves Investors should Listen - news.stocktradersdaily.com
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading Cardiovascular Drug Developer NewAmsterdam Sets Key Investor Presentation - Stock Titan
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 By Investing.com - Investing.com Australia
Newamsterdam Pharma director James Topper buys $25,520 in shares - Investing.com Australia
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National Bank - Defense World
Newamsterdam pharma COO sells shares worth $376,000 By Investing.com - Investing.com Canada
Newamsterdam Pharma director James Topper buys $25,520 in shares By Investing.com - Investing.com South Africa
Newamsterdam Pharma CEO Michael Davidson sells shares for $281,000 - Investing.com India
Newamsterdam pharma COO sells shares worth $376,000 - Investing.com India
Newamsterdam Pharma COO Kling sells $2.36 million in stock By Investing.com - Investing.com Australia
Newamsterdam Pharma COO Kling sells $2.36 million in stock - Investing.com
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DE - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts - Defense World
Financial Metrics Exploration: Understanding NewAmsterdam Pharma Company NV (NAMS) Through Ratios - The Dwinnex
9,983 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Keybank National Association OH - Defense World
(NAMS) Trading Advice - news.stocktradersdaily.com
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News
Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com Australia
Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):